November 2013- Volume 9, Issue 11

November 2013

In this Issue

Tools & Technology

Now hear this

Now hear this

Labcyte teams with AstraZeneca to develop acoustic sample handling for mass spectrometry to advance drug discovery

Sad news for cancer

Sad news for cancer

Stanford-led research uses bioinformatics approach to identify antidepressant that could be cancer-fighter

A 'model' new research center

A 'model' new research center

Bayer and RWTH Aachen University create center for computer-based modeling

Bruker acquires Prairie Technologies

Bruker acquires Prairie Technologies

Acquisition strengthens Bruker Nano Surfaces Division's position in life-science markets

Research & Development

Joslin partners with Pfizer, Lilly on diabetes

Joslin partners with Pfizer, Lilly on diabetes

Companies will predict, treat kidney failure in type 2 diabetes

Academic institutions partner with Takeda in landmark collaboration

Academic institutions partner with Takeda in landmark collaboration

MSKCC, Rockefeller University and Weill Cornell to conduct early-stage drug discovery with pharma

HμREL liver tissue co-culture to be tested by Sanofi

HμREL liver tissue co-culture to be tested by Sanofi

Goal is to validate HμRELhuman for use in preclinical drug development

Sealing the deal

Sealing the deal

After no small amount of controversy, Otsuka reports that it has completed its acquisition of Astex

All together now …

All together now …

IMPROVER launches new challenge, as other major life-science group efforts also continue their own work

Feature

ASCB Annual Meeting Preview: Developing talent

ASCB Annual Meeting Preview: Developing talent

In addition to high-level educational fare, ASCB looks to step up professional development offerings at its annual meeting

Special Reports

Reinventing medicinal chemistry

Reinventing medicinal chemistry

New technologies and attitudes offer medicinal chemists an evolving role in drug discovery

News Briefs

Evotec teams with Johnson & Johnson Innovation to identify novel Alzheimer's Disease therapies

Evotec teams with Johnson & Johnson Innovation to identify novel Alzheimer's Disease therapies

Evotec AG announced its second major collaboration in recent weeks, this time with the Johnson & Johnson Innovation Center in California to identify new targets for Alzheimer's disease drug discovery and development. Under the terms of the agreement, Janssen Pharmaceuticals, Inc., a member of the Johnson & Johnson family of companies, and Evotec will work together to discover and develop novel treatments for Alzheimer's disease.

Government Watch

Supreme Court silences Novartis

Supreme Court silences Novartis

High court declines to hear case questioning whether punitive damages should be awarded in product liability lawsuits

The element of surprise

The element of surprise

FDA to begin unannounced site inspections at Indian facilities

California governor vetoes controversial biosimilars bill

California governor vetoes controversial biosimilars bill

Similar measures pending in several states before FDA has even issued regulatory guidelines

Science under siege

Science under siege

Already facing tough decisions caused by the sequestration, the U.S. government shutdown further stymies American biomedical researchers

Diagnostics

Epigenomics announces completion of private placement, new partnerships

Epigenomics announces completion of private placement, new partnerships

The proceeds from the offering are slated to finance Epigenomics’ current operations and to build and bolster its distribution capacities for its lead product Epi proColon

Business at light speed

Business at light speed

Biosearch Technologies acquires majority stake in LightSpeed Genomics

Linking lipid metabolism

Linking lipid metabolism

Researchers to study how lipid metabolism links psychotic disorders, metabolic co-morbidities

Accelerating solutions

Accelerating solutions

Pacific Biosciences-Roche Diagnostics agreement aims to take DNA sequencing-based products to the clinic

Commentary

Cell sorting for everyone: From the core lab to your lab

Cell sorting for everyone: From the core lab to your lab

When cell-sorting technology first arrived in the late 1970s, it was used by academics and the medical research community to detect, count and characterize cells from the body and environment. As cell-sorting technology evolved and improved, it also became more complex, unfortunately making it less accessible to many researchers. Fortunately, recent advances in instrumentation have led to the development of much smaller, significantly less expensive and much easier-to-use cell-sorting devices, meaning that even basic researchers can now access this useful technology.

Out of Order: Having words

Out of Order: Having words

It can be difficult at times, when discussing various aspects of the pharmaceutical and biotechnology industries, to remember that at the very base of the process is someone who is hurting and afraid. Not a patient population from a clinical trial who act in a statistical manner, but a single individual with his or her own experiences, biases and concerns.

Global News

Long-term vision

Long-term vision

Acino anticipates buyout by private equity firms for $439 million

From iPS to hepatocytes

From iPS to hepatocytes

Japanese researchers develop new, faster method of hepatocyte generation

An oral agreement

An oral agreement

Novo Nordisk and Oramed both pour great effort into promise of oral insulin

Collaborators launch clinical trial for cystic fibrosis

Collaborators launch clinical trial for cystic fibrosis

Galapagos signs $405 million deal with AbbVie to develop new combination therapies for chronic disease

Seeking to streamline

Seeking to streamline

Workforce reductions common as pharma industry aims to restructure

Editor's Focus

It's time now to sing out, though the story never ends

It's time now to sing out, though the story never ends

2,832 pages: How do you measure, measure five years? This editorial column will be my last in Drug Discovery News, as in a few short weeks, I will be stepping down from my post as chief editor of the news organization and entering a new chapter in my life. As I clean up my office and prepare to pass the baton to Jeff Bouley, who will be your new chief editor in 2014, I am reflecting with great fondness some of the amazing people I have met and the remarkable experiences I have had in the past five and a half years of leading our editorial team in the creation of these pages. Thus, as I exit stage left, I will take inspiration from the song “Seasons of Love” from the hit musical “Rent” (which explains my headline and lead, if you’re not familiar with it) and recall some of the memorable ways in which I will measure my tenure.

Omics & Systems Biology

Finding significant DNA mutations

Finding significant DNA mutations

Dozens of cancer triggers identified and ranked using new tool that scans conserved regions of non-coding DNA

A messenger with punch

A messenger with punch

CureVac, Janssen partner to develop mRNA-based influenza vaccine

Going large with the liver

Going large with the liver

TGen-led GWAS study identifies genes associated with unhealthy liver function

Going GLOBAL

Going GLOBAL

Illumina, G3 team up on massive pan-omic cardiovascular study
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Drug Discovery News November 2024 Issue

Latest Issue  

• Volume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue